Summary.-Immunotherapy using rat 7s antibodies against plasmacytoma 5563 in C3H mice has been measured carefully. Prior adsorption of antibodies with normal mouse tissues, and supplements of co-optable non-immunized macrophages and lymphocytes enhanced the scope of immunotherapy against established tumours. It is suggested that available co-optable lymphocytes and macrophages are imporant limiting factors in tumour immunotherapy.
IMMUNOTHERAPY of cancer has been the focus of many research workers in recent years. Variable but not radical degrees of success have been achieved. Using specifically immune sera, Gorer and Amos (1956) were able to protect C57/BL mice against subsequent challenge with isogeneic leukaemia, but only retardation of growth was obtained when such specifically immune sera were administered shortly after transplantation of the tumour cells.
Such failures of antibody treatments were followed by attempts to utilize cellular immune mechanisms and lymphocytes from different animals sensitized to the tumour were used, but again with a limited success (Delorme and Alexander, 1964) .
In our own work, an experimental model of ascitic plasmacytoma 5563 in C3H mice has been used where the tumour growth has been measured (Fakhri, 1970) and the paraprotein level provides a reliable yardstick in follow up (Fakhri and Hobbs, 1970a) . The immune reactions of rats to MP5563 have been analysed. While the rat 19s antibodies can be cytotoxic in vitro, in vivo success was limited to the first 24 hours after 1 tumour transplantation and immunized rat lymphocytes were unsuccessful at all times (Fakhri and Hobbs, 1970b) . Rat 7s antibodies had no direct cytotoxicity but it was found they could co-opt lymphocytes from unimmunized animals to form rosettes around tumour cells which were killed about 20 hours later (Fakhri and Hobbs, 1972) . Rat 7s antibodies could also co-operate with macrophages, resulting in tumour cell death within 1-2 hours. The quantitation available within the present experimental model showed that if tumour cells were first coated with rat 7s antibodies then the LD50 inoculum had to be increased by over 200 times. This increased inoculum of 200,000 tumour cells presumably reflected the co-optable capacity of. the peritoneal cavity of the mouse, and this seemed to be the limiting factor in the present tumour immunotherapy.
The object of the present studies was to see if (1) the use of rat 7s antibodies adsorbed with normal mouse tissues would cut down wastage and (2) if supplements of macrophages and lymphocytes could bring more extensive tumours under control. Mouse plasmacytoma 5563 was grown in ascitic form using intraperitoneal transplantation in C3H mice from both sexes (8-12 weeks old). Albino rats (males 3-6 months old) were used to raise antibodies to the MP 5563. The immunization procedure, thoracic duct cannulation and preparation of purified rat anti-mouse 7s antibodies were as described elsewhere (Fakhri and Hobbs, 1970a, 1972) . Adsorbed 7s anti-tumour antibodies were prepared using 4 spleens freshly collected from sacrificed C3H mice. These were cut up and squeezed with forceps and the washed suspension was added to 20 ml of purified 7s antibodies. The mixture was stirred for 30 minutes at room temperature and then centrifuged to collect the supernatant. The in vitro activity of the 7s antibodies adsorbed with mouse spleen cells was tested. Co-option of rat lymphocytes to form rosettes around the tumour cells still occurred though the adsorbed antibody was weaker than the unadsorbed one.
The in vivo effects of the adsorbed and unadsorbed 7s antitumour antibodies were tested. Three groups of 5 mice (A, B and C) were transplanted with 250,000 tumour cells each. Group A were left untreated as controls. Two hours after transplantation Group B were injected intraperitoneally with 1 ml of unadsorbed 7s antibody and Group C were similarly injected with 1 ml of adsorbed 7s antibody. The average survivals of the 3 groups are shown in Table I . The in vivo effects of adsorbed 7s antibodies supplemented with additional lymphocytes and peritoneal macrophages were then tested. In 5 groups of 5 mice (D-H), each mouse was given 250,000 tumour cells, representing 250 times the LD50. Group D were given no treatment to provide controls. In Group E the intraperitoneal treatment was 1 ml adsorbed 7s antibodies together with 10 million lymphocytes collected on the second day of drainage (when co-optable lymphocytes are at least 40 % of the total) from the thoracic duct of an unimmunized rat. In Group F, G and H the cells used together with the 1 ml of adsorbed 7s antibodies were from the freshly collected peritoneal washouts of normal mice. Each tumour-bearing mouse in Group F was supplemented from a single normal mouse, providing about 1 million macrophages and about 1 million nonimmune lymphocytes, given at 24 hours after tumour transplantation. In Group G, H the supplement was increased three-fold and given at 48 and 72 hours respectively. A further control group received one additional peritoneal washout without any antibody at 24 hours after transplantation and all died at 14 days, showing no effect from non-immune macrophages and lymphocytes when given alone.
DISCUSSION
The co-operations between lymphocytes and antibodies ( Fig. 1) (Fakhri and Hobbs, 1972 ) and macrophages and antibodies ( Fig. 2) (Fakhri, McLaughlin and Hobbs, 1972 ) within the present experimental model have already been reported. Table I it can be seen that the adsorbed 7s antibodies of the rat were more effective than the unadsorbed. This is presumably because the limited number of macrophages normally available in the peritoneal cavity were all directed against the tumour rather than against the normal mouse tissues as well, as when using the unadsorbed antibodies. Although the tumour MP 5563 originally arose spontaneously in C3H mice, presumably it still has tumour specific antigen(s) different from that of the normal C3H mouse tissues. This was demonstrated by the ability of the antibodies to form rosettes after being adsorbed with C3H cells, including normal B-lymphocytes.
From previous studies, a doubling Fig. 2 ).
The lengthening of survival from 14 to 18 days in Group C and E may not seem impressive, but if human myelomatosis takes 21 years to develop from a single cell (Hobbs, 1971 ) and this mouse tumour 30 days, the 4 additional days would be comparable to a 3-year remission in man. This is slightly better than the average of 2 years on current chemotherapy.
The lengthening of survival in Group H by 6-21 days could be considered equivalent to remissions of 4-14 years in man. This group is especially encouraging in that by 72 hours the paraprotein was detectable in the plasma of all mice and at levels (ca. 0 5 g/100 ml) to which current chemotherapy reduces human paraproteins in some 200% of patients.
The myelomata of such patients enjoy easy access through the rich blood supply of the bone marrow. Therefore the possibility of using co-opting antibodies against human myeloma (partially adsorbed with the patient's normal buffy coat) supplemented by intravenous macrophages and lymphocytes (which can be harvested from peritoneal dialysates or using the Aminco Celltrifuge) is worthy of exploration. This work has been made possible by the generous support of the Cancer Research Campaign.
